Goydos et al. [72] performed a 3-year study assessing serum IL-6 in patients with bile duct cancer, and found that serum IL-6 was significantly higher in cholangiocarcinoma compared to patients with hepatocellular carcinoma, metastatic colorectal cancer and benign bile disease. This evidence concerns the gene IL6 and hepatocellular carcinoma.